PRECIGEN, INC. (PGEN) Form 8-K — Aug 4, 2026
Precigen reported a historic second quarter, with PAPZIMEOS net revenue of $53.1 million — more than double the prior quarter — driving the company to quarterly net income of $20.1 million ($0.06 basic / $0.05 diluted EPS) versus a $26.6 million net loss in the year-ago quarter. Total Q2 revenues were $55.0 million, up $54.1 million year over year. The commercial launch is scaling rapidly: over 500 patients have enrolled through the patient hub, payer coverage spans roughly 315 million US lives, a permanent J-code (J3404) took effect April 1, 2026, and the FDA granted PAPZIMEOS seven years of market exclusivity.
Key figures
- Eps
- $0.06 basic / $0.05 diluted (Q2 2026)
- Revenue
- 55000000
- Guidance
- Cash plus PAPZIMEOS proceeds expected to support cash flow break-even by end of 2026; R&D expenses expected to increase as the year progresses; continued PAPZIMEOS demand growth seen in Q3 2026
- Net Income
- 20100000
- Total Debt
- 93880000
- Revenue Yoy
- $54.1 million increase vs. Q2 2025 ($55.0M vs. $0.9M)
- Total Assets
- 170296000
- Cash Position
- $38.7 million in cash, cash equivalents, and investments as of June 30, 2026
- Shares Outstanding
- 356,893,568 weighted average basic shares (Q2 2026)
- J code
- J3404, effective April 1, 2026
- Payer coverage
- approximately 315 million US lives (~100% of insured lives)
- H1 2026 net income
- $12.1 million ($0.03 basic and diluted EPS)
- Market exclusivity
- seven years (FDA)
- H1 2026 total revenue
- $78.2 million
- Prior year q2 net loss
- $(26.6) million ($(0.09) basic and diluted EPS)
- Operating income q2 2026
- $22.6 million
- Papzimeos h1 2026 revenue
- $74.7 million
- Papzimeos q2 2026 revenue
- $53.1 million
- Papzimeos patient hub enrollment
- well over 500 patients
Price after filing
Close on the filing date to close N calendar days later (from $5.94). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.